Survodutide and tirzepatide are both dual receptor agonists given as once-weekly injections, but they pair GLP-1 with a different second receptor and sit at different regulatory stages. Tirzepatide is FDA-approved and widely used, while survodutide remains investigational, so the evidence behind each is not on equal footing.
Reviewed for accuracy · Last reviewed July 8, 2026The clearest practical difference is regulatory. Tirzepatide has an approved label, a defined titration, and Phase 3 evidence, whereas survodutide is still investigational: it has Phase 2 data in obesity and in MASH with Phase 3 obesity trials ongoing, but no approved dose or long-term human safety record.
Mechanistically the two differ in their second target. Both use the GLP-1 arm, but survodutide pairs it with glucagon (proposed to add effects on liver fat and energy expenditure), while tirzepatide pairs it with GIP. The glucagon arm is why survodutide has also been studied in MASH. Whether either receptor pairing is preferable in practice is not something the current evidence lets anyone state as fact.
Both were studied as once-weekly subcutaneous injections with gradual dose escalation, and both reported predominantly dose-related gastrointestinal side effects. Neither of these summaries is a substitute for medical advice about which, if either, is appropriate.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Survodutide is investigational. Talk to a doctor before starting any compound.